Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company ...

Traws Pharma is burning cash In November, Traws Pharma reported $8.5 million of net loss for its third quarter that translates to $8.81 per share. The number was up significantly from $4.7 million ...

About Traws Pharma, Inc. Antiviral ProgramTraws Pharma is a clinical stage biopharmaceutical company developing potential oral small molecule therapies for the treatment of respiratory viral diseases.

Access Traws Pharma stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases ...

Traws Pharma (TRAW) announced progress in the development of its investigational one-dose influenza investigational therapy, tivoxavir marboxil for treatment of H5N1 bird flu. “In laboratory ...

Traws Pharma earnings missed by $4.62, revenue fell short of estimates ...

NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage ...

In vivo study in mice, with H5N1 isolated from an infected dairy worker, showed potent protection and suppression of virus replication in lungs Phase 2 study expected to begin in H1 2025 Traws ...